Search Results

Scientists from Colossal Biosciences, the world’s first de-extinction company, and the University of Melbourne announce a major step forward in the effort to save Australia’s endangered northern quoll from the invasive cane toad.

Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has concluded a commercialization agreement in northern Europe for its innovative rescue therapy for epileptic seizures ZEPIZURE®, previously known as ZENEO® Midazolam, covering Germany, the UK, Denmark, Sweden, Finland and Norway.

Colossal Biosciences, the world’s first de-extinction company, and BioRescue, a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction.

This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.

WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.

Biologics Market Outlook 2024-2032:

Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine.

With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.